Literature DB >> 15369638

Interleukin-2 receptor alpha-chain expression in patients with alopecia areata.

Ines Brajac1, Franjo Gruber, Mladen Petrovecki, Danijela Malnar-Dragojević.   

Abstract

Interleukin-2 (IL-2) is a lymphokine produced by activated T-cells. Its receptor, IL-2R, is expressed on T-cells. Several clinical and experimental findings point towards IL-2 as a crucial mediator inducing immunologic reaction against human follicle in alopecia areata. The objective of our study was to analyze the expression of IL-2R as a sign of T-cell activation in scalp biopsies of patients suffering from alopecia areata. An immunohistochemical analysis was used to determine the difference in cytokine-regulated expression of IL-2R between 45 patients with active and stable phase of alopecia areata and 23 healthy control subjects. In the patients with alopecia areata in active phase, the expression of IL-2R in scalp biopsies was significantly stronger than that in the patients with stable disease and in controls. The increase of IL-2R+ cells in early phase of the disease could suggest that T-lymphocyte activation with IL-2 secretion and IL-2R expression may initiate the immune inflammatory mechanism of alopecia areata.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15369638

Source DB:  PubMed          Journal:  Acta Dermatovenerol Croat        ISSN: 1330-027X            Impact factor:   1.256


  6 in total

1.  Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition.

Authors:  Luzhou Xing; Zhenpeng Dai; Ali Jabbari; Jane E Cerise; Claire A Higgins; Weijuan Gong; Annemieke de Jong; Sivan Harel; Gina M DeStefano; Lisa Rothman; Pallavi Singh; Lynn Petukhova; Julian Mackay-Wiggan; Angela M Christiano; Raphael Clynes
Journal:  Nat Med       Date:  2014-08-17       Impact factor: 53.440

2.  Inhibiting Janus kinases to treat alopecia areata.

Authors:  Sherrie J Divito; Thomas S Kupper
Journal:  Nat Med       Date:  2014-09       Impact factor: 53.440

3.  Case Report: A Case of Myeloproliferative Neoplasm Complicated by Alopecia Areata.

Authors:  Yotaro Tamai; Shinichi Teshima; Shun Tsunoda; Wataru Kamata; Shuku Sato
Journal:  Front Med (Lausanne)       Date:  2022-05-26

4.  Serum Levels of Interleukin-2 in Patients with Alopecia Areata: Relationship with Clinical Type and Duration of the Disease.

Authors:  Emina Kasumagić-Halilovic; Semra Cavaljuga; Nermina Ovcina-Kurtovic; Lamija Zecevic
Journal:  Skin Appendage Disord       Date:  2018-02-06

5.  Alopecia areata, primary sclerosing cholangitis, and ulcerative colitis: autoimmunity and apoptosis as common links?

Authors:  Panagiotis Katsinelos; Jannis Kountouras; George Paroutoglou; Christos Zavos
Journal:  Dig Dis Sci       Date:  2007-03-20       Impact factor: 3.487

6.  Serum level of interleukin-15 in active alopecia areata patients and its relation to age, sex, and disease severity.

Authors:  Magdy Abd El Aziz Ragab; Eman Mohamed Hassan; Dalia Abd El Moaty El Niely; Mai Mahmoud Mohamed
Journal:  Postepy Dermatol Alergol       Date:  2021-01-06       Impact factor: 1.837

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.